Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of SA001 in Healthy Male Volunteers
NCT02470286Phase 1Completed
- Sponsor
- Samjin Pharmaceutical Co., Ltd.
- Start
- Jun 2015
- Primary completion
- Sep 2015
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rebamipide mofetil in dry eye syndrome (DED) and Sjögren's syndrome (5 cohorts), sponsored by Samjin Pharmaceutical Co., Ltd. Primary endpoint: The incidence of treated related adverse event. Started Jun 2015; status: completed.
02
Drugs
rebamipide mofetil
03
Conditions
dry eye syndrome (DED)Sjögren's syndrome
Beyond the preview
Go deeper on NCT02470286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02470286.